相关实验视频
Updated: Jun 19, 2025
08:02
A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
Published on: March 24, 2023
3.4K
药理上抑制Il6st/gp130可以改善皮肤炎症和
Minseok Kim1, Chaeeun Kim1, Haiyan Zheng1
1Department of Biomedical Sciences, Korea University College of Medicine, Seoul 02841, Republic of Korea.
概括
药理上抑制干白素6信号转换器 (Il6st) 为慢性皮肤炎提供了一个有前途的新治疗策略. 向Il6st可能会减少炎症并改善皮肤状况,这代表了这种广泛传播的疾病的新方法.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性皮肤炎涉及复杂的细胞因子信号通路,有助于炎症.
- 干白素6信号转换器 (Il6st),也称为糖蛋白130 (Gp130),对于放大促炎性细胞因子信号至关重要.
- 现有的皮肤炎治疗方法存在局限性,这凸显了对新型治疗点的需求.
研究的目的:
- 在慢性皮肤炎模型中研究抑制Il6st的治疗潜力.
- 评估小分子IL6st抑制剂在减少皮肤炎病理和相关症状方面的疗效.
主要方法:
- 使用了一种1-chloro-2,4-dinitrobenzene诱导的慢性皮肤炎的小鼠模型.
- 用了两个不同的小分子IL6st抑制剂,SC-144和bazedoxifene.
- 评估了皮肤状况的改善,细胞因子表达的正常化和性行为.
- 同时还检查了因伊米奎莫德诱导的牛皮病模型中的效应.
主要成果:
- SC-144和bazedoxifene在皮肤炎皮肤状况中显示出中度但显著的改善.
- 用SC-144治疗导致了皮肤炎的标志性特定细胞因子表达的正常化.
- 抑制剂在皮肤炎模型中有效地减轻了的行为.
- 在伊米基莫德诱导的牛皮模型中,效应不那么明显.
结论:
- 药理上抑制Il6st可以改善皮肤炎的病理性刺激.
- 它在皮肤炎的病理机制中起着重要作用.
- Il6st代表了一种新的,可翻译的治疗点,用于治疗慢性皮肤炎.
相关概念视频
01:24T Cell Types and Functions
986
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
986
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
01:19Antiasthma Drugs: Leukotriene Modifiers
269
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
269
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
126
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
126